<DOC>
	<DOCNO>NCT00530127</DOCNO>
	<brief_summary>The primary objective study demonstrate safety tolerability deferiprone subject Friedreich 's ataxia ( FRDA ) . The secondary objective evaluate efficacy deferiprone treatment FRDA , assess 9-Hole Peg Test ( 9HPT ) , Timed 25-Foot Walk ( T25FW ) , Low-Contrast Letter Acuity test ( LCLA ) , International Cooperative Ataxia Rating Scale ( ICARS ) , Friedreich 's Ataxia Rating Scale ( FARS ) . The tertiary objective evaluate effect deferiprone : 1. cardiac function measure change Left Ventricular Shortening Fraction ( LVSF ) , Left Ventricular Ejection Fraction ( LVEF ) Left Ventricular ( LV ) mass use echocardiogram ( ECHO ) , 2. quality life use quality-of-life survey , 3. functional status use Activities Daily Living ( ADL ) .</brief_summary>
	<brief_title>A Study Investigating Safety Tolerability Deferiprone Patients With Friedreich 's Ataxia</brief_title>
	<detailed_description>This multi-centre , double-blind , randomize , placebo-controlled clinical trial . A total 80 patient Friedreich 's ataxia enrol . Eligible patient receive deferiprone oral solution placebo total daily dose 20 mg/kg/day , 40 mg/kg/day 60 mg/kg/day , divide two-daily dos 6 month .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>1 . Diagnosis FRDA , confirm mutation ( excludes point mutation ) frataxin ( FXN ) gene GAA repeat ≥ 400 short allele . 2 . Males female age 7 35 year . 3 . No exposure idebenone , coenzyme Q10 , vitamin C , vitamin E antioxidant supplement drug therapy period least one month prior start treatment study . 4 . Neurological testing : A FARS score &gt; 20 &lt; 85 Screening Baseline . 5 . Female subject childbearing potential must negative pregnancy test Baseline . 6 . If subject heterosexual , sexuallyactive male , confirm and/or female partner use effective method contraception length trial 30 day follow completion study early termination . 7 . Signed witness write informed consent/assent , obtain prior first study intervention , well ability adhere study restriction , appointment evaluation schedule . 1 . Iron deficiency define ferritin level reference range age sexmatched control 2 . Unable complete T25FW AND score &gt; 5 minute 9HPT . ( Subjects complete T25FW score ≤ 5 minute 9HPT allow enroll score double compare screening ) . 3 . Abnormal ALT , great 2.0 time upper limit normal two consecutive assessment . 4 . Serum creatinine outside normal reference range . 5 . History evidence neutropenia define absolute neutrophil count ( ANC ) &lt; 1.5 x 109/L thrombocytopenia define platelet count &lt; 150 x 109/L . 6 . Refusal participate screening procedure unable participate screening procedure unable comply requirement protocol . 7 . Receiving investigational drug product receive investigational product within 30 day prior enrollment study . 8 . Subjects previously take deferiprone . 9 . Subjects , opinion Investigator , represent poor medical , psychological psychiatric risk , participation investigational trial would unwise . 10 . Pregnant , breastfeed plan become pregnant study period . 11 . History malignancy . 12 . History alcohol drug abuse . 13 . Investigators , site personnel directly affiliate study immediate family . Immediate family define spouse , parent , child sibling , whether biological legally adopt . 14 . Hypersensitivity active substance ( deferiprone ) excipients oral solution . 15 . QT interval &gt; 450 msec Baseline .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Friedreich 's ataxia</keyword>
</DOC>